Entera Bio Ltd. (ENTXW)
2025-06-30 | ||||
|---|---|---|---|---|
| Revenues | - | |||
| Cost of revenue | - | |||
| Gross profit | - | |||
| Research and development expense | 1,520,000 | |||
| General and administrative expense | 1,148,000 | |||
| Net expenses related to opko collaboration agreement | 2,668,000 | |||
| Operating loss | -2,668,000 | |||
| Financial income, net | 12,000 | |||
| Net loss | -2,656,000 | |||
| Earnings per share, basic and diluted | 0.06 | |||
| Earnings per share, diluted | 0.06 | |||
| Weighted average number of shares outstanding, basic and diluted | 46,836,700 | |||
| Weighted average number of shares outstanding, diluted | 46,836,700 | |||